Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyNadifloxacin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Nadifloxacin
- Accession Number
- DB12447
- Type
- Small Molecule
- Groups
- Investigational
- Description
Nadifloxacin has been used in trials studying the treatment of Acne Vulgaris.
- Structure
Structure for DB12447 (Nadifloxacin)
- Synonyms
- Not Available
- Categories
- UNII
- 6CL9Y5YZEQ
- CAS number
- 124858-35-1
- Weight
- Average: 360.385
Monoisotopic: 360.148535327 - Chemical Formula
- C19H21FN2O4
- InChI Key
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)
- IUPAC Name
- 7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.0⁵,¹³]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
- SMILES
- CC1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCC(O)CC1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Nadifloxacin. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Nadifloxacin. Experimental Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Nadifloxacin. Approved, Investigational, Withdrawn BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Nadifloxacin. Investigational Bevacizumab Bevacizumab may increase the cardiotoxic activities of Nadifloxacin. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nadifloxacin. Approved Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Nadifloxacin. Approved, Investigational Cymarin Cymarin may decrease the cardiotoxic activities of Nadifloxacin. Experimental Deslanoside Deslanoside may decrease the cardiotoxic activities of Nadifloxacin. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Nadifloxacin. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Nadifloxacin. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nadifloxacin. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Nadifloxacin. Approved, Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Nadifloxacin. Experimental Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Nadifloxacin. Experimental Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Nadifloxacin. Experimental Oleandrin Oleandrin may decrease the cardiotoxic activities of Nadifloxacin. Experimental, Investigational Ouabain Ouabain may decrease the cardiotoxic activities of Nadifloxacin. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nadifloxacin. Approved, Vet Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Nadifloxacin. Experimental Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nadifloxacin. Approved Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Nadifloxacin. Experimental Trastuzumab Trastuzumab may increase the cardiotoxic activities of Nadifloxacin. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 4410
- PubChem Substance
- 347828688
- ChemSpider
- 4257
- ChEBI
- 31889
- ChEMBL
- CHEMBL363449
- Wikipedia
- Nadifloxacin
- ATC Codes
- D10AF05 — Nadifloxacin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Acne Vulgaris 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.632 mg/mL ALOGPS logP 0.87 ALOGPS logP 1.84 ChemAxon logS -2.8 ALOGPS pKa (Strongest Acidic) 6.13 ChemAxon pKa (Strongest Basic) 0.44 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 81.08 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 96.03 m3·mol-1 ChemAxon Polarizability 36.53 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-03dl-0019000000-5a82af9804b7e75eddaa
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Fluoroquinolones / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Aryl fluorides / Benzenoids / Piperidines show 11 more
- Substituents
- Quinoline-3-carboxylic acid / Fluoroquinolone / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Dialkylarylamine / Tertiary aliphatic/aromatic amine show 27 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- quinolone antibiotic, hydroxypiperidine, pyridoquinoline, heteroarylpiperidine (CHEBI:31889)
Drug created on October 20, 2016 16:25 / Updated on July 02, 2018 19:36